For the past year, experts across various disciplines have studied and carefully considered each new piece of evidence about treatment strategies for COVID-19 and translated it into standardized guidelines for Yale School of Medicine and Yale New Haven Health System clinicians
- July 28, 2020Source: YaleNews
Known as LAM-002A (apilimod), the drug has a proven safety record. Preliminary research has shown it can block cellular entry and trafficking of the SARS-CoV-2 virus, the cause of COVID-19.
- July 27, 2020Source: Reuters
(Reuters) - Devon Brumfield could hear her father gasping for breath on the phone.
- April 03, 2020
The scientists and clinicians at Yale School of Medicine (YSM) and the Yale New Haven Health System (YNHHS) have performed herculean feats, and also faced daunting obstacles, as they work to tame the COVID-19 pandemic in Connecticut.
- April 03, 2020
Have a Condition That Can Affect Breathing? What You Need to Know About COVID-19.
- March 17, 2020Source: Infectious Disease Advisor
COVID-19 in Chronic Lung Disease: What You Need to Know
- February 13, 2019Source: PulmonologyAdvisor
Become educated about the role of climate change. Increases in coccidioidomycosis, avian influenza, Hantavirus, and aspergillosis have all been noted to increase in areas with changes in ambient temperature or rainfall.7 The old and young may be more susceptible to rapid changes in conditions. Climate change has already been found to increase rates of COPD and asthma, which increase the risk for infection.
- September 23, 2018Source: https://www.medpagetoday.com/video/meetingcoverage/ers/chest-video-conference-reporter-ers-2018/182/2531
ERS CHEST Video Conference Reporter: ERS 2018
- September 28, 2017Source: American Lung Association
Klebsiella pneumoniae is a germ that causes pneumonia, with a mortality that can reach up to 70 percent when infection spreads to other organs. Current, antibiotic treatment often fails due to development of antibiotic resistance, so there is an urgent need for new therapies. We have found a deficiency in a gene called Chit1, present in up to 20 percent of humans, gives mice a significant advantage during pneumonia. Absence of this gene helps mice limit bacterial spread to other organs and increase survival with or without antibiotic use. Understanding the mechanisms of the advantage provided by Chit1 deficiency will help to develop new therapies that can boost the host defense against bacterial infection to reduce mortality.
- December 01, 2016
This summer, the new Yale Center for Pulmonary Infection Research and Treatment (CPIRT) held its first meeting, with the goal of breathing fresh air into the science of lung infection. Conceived by associate professor Dr. Charles Dela Cruz as a cross-disciplinary hub for investigators, CPIRT brings together innovative minds from basic, translational, and clinical research areas across Yale. The center’s ultimate aim is to develop better treatments for both acute and chronic ailments — from pandemic flu to emphysema — that are affected by lung infections.